PARTICULARITIES OF TREATMENT WITH CONVENTIONAL
SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
(DMARDs) IN A GROUP OF PATIENTS WITH RHEUMATOID
ARTHRITIS
RUXANDRA ELENA SCHIOTIS1,2, DANA GOȘA1, CORINA BOCȘAN1, ȘOIMIȚA SUCIU1*, ANCA DANA BUZOIANU1
1Functional Sciences Department, “Iuliu Haţieganu” University of Medicine and Pharmacy, 8 Victor Babeș Street, Cluj-
Napoca, Romania
2Infectious Diseases Hospital Outpatient Clinic, 19 Moților Street, Cluj-Napoca, Romania
*corresponding author: ssuciu@yahoo.com
Download Full Article

Abstract:
Rheumatoid arthritis (RA) is a systemic inflammatory disease with destructive joint damage, causing severe functional
impairment. Due to the complex mechanism of action of the various representatives from the group of conventional synthetic
(CS) DMARDs, the different side-effect profile and the variability in patient response to treatment, the therapeutic
management of RA with CS DMARDs is a real challenge in everyday clinical practice. The present study aims to identify the
specific features of treatment with conventional agents in a group of RA patients monitored in an outpatient clinic. The
present study was an observational, retrospective, descriptive cohort type of study, in witch, we included patients diagnosed
with RA under treatment only with CS DMARDs (30 patients). Demographic, clinical and treatment data were registered and
also adverse reactions to treatment. Effectiveness of treatment was evaluated using disease activity score for RA (DAS28).
All data presented are expressed as mean ± SD for continuous variables and as number and/or percentage for categorical
variables. The analysis of the treatment plan showed that methotrexate (MTX) was the most frequently prescribed
conventional drug as first line therapy in 26 (87%) of the patients, in monotherapy. It was registered that only 5 (17%) of the
analysed patients received CS DMARD in monotherapy and 25 (83%) in combination therapy. In our study group, the
recommended treatment was considered effective in 53% of cases. One in three patients experienced adverse reactions to
therapy. The most common adverse reactions were muco-cutaneous, followed by respiratory and digestive ones. The most
prescribed CS DMARDs was MTX and the most used therapeutic strategy was step-up combination therapy. The initial
treatment plan ensured the effective control of the disease in about half of RA patients. The adverse reactions of CS
DMARDs agents were not of vital importance.

Top